CD44 and central nervous system cancer: One meta-analysis claims higher expression of CD44 that predicts poor survival in glioma particularly in those with WHO grades II and III glioma (52), and another clinical research discovers that higher tumor expression of CD44 acts as a negative prognosis indicator in patients with GBM (53).